triclabendazole sulfoxide has been researched along with ziprasidone in 1 studies
| Studies (triclabendazole sulfoxide) | Trials (triclabendazole sulfoxide) | Recent Studies (post-2010) (triclabendazole sulfoxide) | Studies (ziprasidone) | Trials (ziprasidone) | Recent Studies (post-2010) (ziprasidone) |
|---|---|---|---|---|---|
| 30 | 1 | 16 | 1,068 | 254 | 362 |
| Protein | Taxonomy | triclabendazole sulfoxide (IC50) | ziprasidone (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.005 | |
| Aspartate aminotransferase, cytoplasmic | Homo sapiens (human) | 5.39 | |
| D | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.011 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0004 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2301 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR | 1 |
1 other study(ies) available for triclabendazole sulfoxide and ziprasidone
| Article | Year |
|---|---|
In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Topics: Acetates; Albendazole; Aldicarb; Biotransformation; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Humans; Isoenzymes; Methiocarb; Microsomes, Liver; Piperazines; Quinolines; Risk Assessment; Sulfides; Sulfones; Sulfoxides; Thiazoles; Triclabendazole | 2018 |